Nykode Therapeutics AS (VACBF) News Today $0.52 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Nykode Therapeutics AS (5VB.DU)September 17, 2024 | finance.yahoo.comNykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based VaccinesAugust 14, 2024 | globenewswire.comNykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 MeetingJune 20, 2024 | globenewswire.comNykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior EfficacyJune 11, 2024 | globenewswire.comNykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical CancerMay 14, 2024 | globenewswire.comNykode Therapeutics - Quarterly report Q1 2024May 14, 2024 | globenewswire.comNykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical CancerApril 19, 2024 | globenewswire.comNykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical CancerMarch 21, 2024 | globenewswire.comNykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune DiseasesMarch 19, 2024 | globenewswire.comNykode Therapeutics - Quarterly report Q3 2023January 29, 2024 | finance.yahoo.com Get Nykode Therapeutics AS News Delivered to You Automatically Sign up to receive the latest news and ratings for VACBF and its competitors with MarketBeat's FREE daily newsletter. Email Address This is treason (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. VACBF Media Mentions By Week VACBF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VACBF News Sentiment▼0.000.41▲Average Medical News Sentiment VACBF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VACBF Articles This Week▼00▲VACBF Articles Average Week Get Nykode Therapeutics AS News Delivered to You Automatically Sign up to receive the latest news and ratings for VACBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BRRGF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:VACBF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nykode Therapeutics AS Please log in to your account or sign up in order to add this asset to your watchlist. Share Nykode Therapeutics AS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
